Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
306 participants
INTERVENTIONAL
2009-06-30
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Duration of Doxycycline Treatment in EM Patients
NCT03153267
Antibiotic Treatment of Multiple Erythema Migrans
NCT01163994
Duration of Doxycycline Treatment in MEM Patients
NCT03337932
Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
NCT01518192
Doxycycline in Therapy of Erythema Migrans
NCT01475708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EM-10 days doxycycline
doxycycline
doxycycline 100 mg bid, 10 days
EM-doxycycline 15 days
doxycycline
doxycycline 100 mg bid, 15 days
controls
placebo
control subjects without a history of Lyme borreliosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
doxycycline
doxycycline 100 mg bid, 10 days
doxycycline
doxycycline 100 mg bid, 15 days
placebo
control subjects without a history of Lyme borreliosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnancy or lactation
* immunocompromised status
* serious adverse event to doxycycline
* taking antibiotic with antiborrelial activity within 10 days
* multiple erythema migrans or extracutaneous manifestations of Lyme borreliosis
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Franc Strle
M.D., PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franc Strle, MD
Role: STUDY_CHAIR
UMC Ljubljana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMC Ljubljana, Department of Infectious Diseases
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Veluscek M, Bajrovic FF, Strle F, Stupica D. Doxycycline-induced photosensitivity in patients treated for erythema migrans. BMC Infect Dis. 2018 Aug 3;18(1):365. doi: 10.1186/s12879-018-3270-y.
Stupica D, Lusa L, Ruzic-Sabljic E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012 Aug;55(3):343-50. doi: 10.1093/cid/cis402. Epub 2012 Apr 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EM-0509
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.